Gene: BRAF ×
Source: ALL
Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 673
Gene Symbol: BRAF
BRAF 		0.100 GeneticVariation disease BEFREE The role of KRAS and BRAF mutations and ALK rearrangement in lung cancer-targeted therapy, are also reviewed. 21463141 2011
Entrez Id: 673
Gene Symbol: BRAF
BRAF 		0.100 GeneticVariation disease BEFREE Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. 27834212 2016
Entrez Id: 673
Gene Symbol: BRAF
BRAF 		0.100 GeneticVariation disease BEFREE The incidence of BRAF mutations other than V600E is significantly higher in lung cancer than in melanoma. 21483012 2011
Entrez Id: 673
Gene Symbol: BRAF
BRAF 		0.100 GeneticVariation disease BEFREE The frequency of BRAF mutations in lung cancer was low in an Asian cohort. 24297085 2014
Entrez Id: 673
Gene Symbol: BRAF
BRAF 		0.100 Biomarker disease BEFREE Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. 24550319 2014
Entrez Id: 673
Gene Symbol: BRAF
BRAF 		0.100 GeneticVariation disease BEFREE Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. 22649091 2012
Entrez Id: 673
Gene Symbol: BRAF
BRAF 		0.100 GeneticVariation disease BEFREE BRAF mutated lung cancer is a genetically distinct subtype that occurs in 2-5% of non-small cell lung carcinomas (NSCLC). 28625649 2017
Entrez Id: 673
Gene Symbol: BRAF
BRAF 		0.100 GeneticVariation disease BEFREE Although a few Caucasian lung cancer patients harbored BRAF mutations, there have been no reports about the BRAF mutation in Japanese patients with lung cancer. 16376942 2006
Entrez Id: 673
Gene Symbol: BRAF
BRAF 		0.100 GeneticVariation disease BEFREE We developed a highly sensitive LUNG CANCER (LC)-biochip approach for the detection of the most common EGFR, KRAS, PIK3CA, and BRAF gene mutations. 25153497 2015
Entrez Id: 673
Gene Symbol: BRAF
BRAF 		0.100 GeneticVariation disease BEFREE In this study, using both novel and established technologies, we developed a clinically practical assay to survey the status of three frequently mutated genes in lung cancer (EGFR, K-ras and TP53) and two genes (BRAF and β-catenin) with known hotspot mutations in many other cancers. 22407457 2012